A carregar...
Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study
It has been hypothesized that low levels of C1 esterase inhibitor (C1-INH), a key inhibitor of the complement pathway, may play a role in the occurrence of adverse events (AEs) associated with intravenous immunoglobulin (IVIG) therapy. This open-label pilot study evaluated C1-INH replacement, with r...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7962274/ https://ncbi.nlm.nih.gov/pubmed/33737935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.632744 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|